JP2018509380A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509380A5 JP2018509380A5 JP2017532715A JP2017532715A JP2018509380A5 JP 2018509380 A5 JP2018509380 A5 JP 2018509380A5 JP 2017532715 A JP2017532715 A JP 2017532715A JP 2017532715 A JP2017532715 A JP 2017532715A JP 2018509380 A5 JP2018509380 A5 JP 2018509380A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- solvate
- hydrate
- following formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 58
- 150000003839 salts Chemical class 0.000 claims description 42
- 239000012453 solvate Substances 0.000 claims description 42
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 11
- 206010065687 Bone loss Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 206010047115 Vasculitis Diseases 0.000 claims description 5
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 208000020084 Bone disease Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 206010039710 Scleroderma Diseases 0.000 claims description 4
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 4
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 210000000270 basal cell Anatomy 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 210000003298 dental enamel Anatomy 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 208000010932 epithelial neoplasm Diseases 0.000 claims description 4
- 230000004761 fibrosis Effects 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 210000002997 osteoclast Anatomy 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 208000009137 Behcet syndrome Diseases 0.000 claims description 3
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 2
- 208000027868 Paget disease Diseases 0.000 claims description 2
- 208000016738 bone Paget disease Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 208000027202 mammary Paget disease Diseases 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 206010047112 Vasculitides Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 0 CC(*)(CC1)CCC1NS(c(cc1)cc(F)c1-c(cc1)ccc1C#N)(=O)=O Chemical compound CC(*)(CC1)CCC1NS(c(cc1)cc(F)c1-c(cc1)ccc1C#N)(=O)=O 0.000 description 2
- 239000003814 drug Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201422469 | 2014-12-17 | ||
| GB1422469.5 | 2014-12-17 | ||
| PCT/EP2015/080022 WO2016097001A1 (en) | 2014-12-17 | 2015-12-16 | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509380A JP2018509380A (ja) | 2018-04-05 |
| JP2018509380A5 true JP2018509380A5 (cg-RX-API-DMAC7.html) | 2019-01-24 |
| JP6650942B2 JP6650942B2 (ja) | 2020-02-19 |
Family
ID=54850187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532715A Active JP6650942B2 (ja) | 2014-12-17 | 2015-12-16 | Ｎ−（４−ヒドロキシ−４−メチル−シクロへキシル）−４−フェニル−ベンゼンスルホンアミド化合物、及びｎ−（４−ヒドロキシ−４−メチル−シクロへキシル）−４−（２−ピリジル）−ベンゼンスルホンアミド化合物、ならびにこれらの治療上の使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10005733B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3262028B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6650942B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107108508B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015367528B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2970578C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2899852T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20211877T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE057569T2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT3262028T (cg-RX-API-DMAC7.html) |
| MA (1) | MA41587A (cg-RX-API-DMAC7.html) |
| SI (1) | SI3262028T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016097001A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
| EP3262028B1 (en) | 2014-12-17 | 2021-10-27 | Pimco 2664 Limited | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(-4hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use |
| GB201813312D0 (en) | 2018-08-15 | 2018-09-26 | Modern Biosciences Ltd | Compounds and their therapeutic use |
| GB201905520D0 (en) | 2019-04-18 | 2019-06-05 | Modern Biosciences Ltd | Compounds and their therapeutic use |
| EP4431090A1 (en) | 2023-03-15 | 2024-09-18 | Istesso 1 Limited | Solfonamides acting as mitochondrial complex i modulator compounds |
| GB202308547D0 (en) | 2023-06-08 | 2023-07-26 | Istesso 2 Ltd | Tnf inhibitor combination therapies |
| GB202309515D0 (en) | 2023-06-23 | 2023-08-09 | Istesso 2 Ltd | JAK inhibitor and IL-6 inhibitor combination therapies |
| GB202315822D0 (en) | 2023-10-16 | 2023-11-29 | Istesso 3 Ltd | Anti-fibrotic combination therapeutics |
| GB202317050D0 (en) | 2023-11-07 | 2023-12-20 | Istesso 2 Ltd | Disease modifying anti-rheumatic drug combination therapies |
| EP4647071A1 (en) * | 2024-05-10 | 2025-11-12 | Istesso Therapeutics Limited | Mitochondrial complex i modulator for use in the treatment of arthritis |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB597810A (en) | 1943-04-12 | 1948-02-04 | Gen Printing Ink Corp | Improvements in or relating to derivatives of diphenyl |
| DE1046220B (de) | 1956-04-21 | 1958-12-11 | Bayer Ag | Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen |
| US4119784A (en) | 1977-07-01 | 1978-10-10 | American Cyanamid Company | Anionic substituted sulfonamido biphenyls |
| DE3000519A1 (de) | 1979-02-01 | 1980-08-14 | Byk Gulden Lomberg Chem Fab | Sulfonamido-alkansaeuren, ihre verwendung und herstellung sowie sie enthaltende arzneimittel |
| DE3535167A1 (de) | 1985-10-02 | 1987-04-09 | Boehringer Mannheim Gmbh | Neue sulfonyl-phenyl(alkyl)amine, verfahren zu ihrer herstellung sowie arzneimittel |
| IL118325A0 (en) | 1995-05-25 | 1996-10-31 | Pont Merck And Pharmaceutical | Integrin receptor antagonists and pharmaceutical compositions containing them |
| AU1118097A (en) | 1995-10-30 | 1997-05-22 | Smithkline Beecham Corporation | Protease inhibitors |
| US5760028A (en) | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| AU2421797A (en) | 1996-03-15 | 1997-10-01 | Du Pont Pharmaceuticals Company | Spirocycle integrin inhibitors |
| PL331338A1 (en) | 1996-07-22 | 1999-07-05 | Monsanto Co | Thiosulphonamidic metaloprotease inhibitors |
| AU731737B2 (en) | 1996-10-16 | 2001-04-05 | Wyeth Holdings Corporation | The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| AU5362998A (en) | 1996-11-27 | 1998-06-22 | Du Pont Pharmaceuticals Company | Novel integrin receptor antagonists |
| AU6780398A (en) | 1997-03-28 | 1998-10-22 | Du Pont Merck Pharmaceutical Company, The | Heterocyclic integrin inhibitor prodrugs |
| HUP0002951A3 (en) | 1997-05-08 | 2002-10-28 | Smithkline Beecham Corp | Bis-aminomethylcarbonyl compounds as protease inhibitors and pharmaceutical compositions containing them |
| DE19719621A1 (de) | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
| DE59802394D1 (de) | 1997-05-09 | 2002-01-24 | Hoechst Ag | Substituierte Diaminocarbonsäuren |
| US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| AP1269A (en) | 1998-01-23 | 2004-04-03 | Aventis Pharma Deutschland Gmbh | Novel salfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion. |
| EP1053226A1 (en) | 1998-02-04 | 2000-11-22 | Novartis AG | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
| JPH11246527A (ja) | 1998-03-02 | 1999-09-14 | Shionogi & Co Ltd | Ｍｍｐ−８阻害剤 |
| DE19815547C1 (de) | 1998-04-07 | 1999-12-02 | Joachim Schmidt | Haftmittel für Zahnprothesen |
| EP0960882A1 (en) | 1998-05-19 | 1999-12-01 | Hoechst Marion Roussel Deutschland GmbH | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists |
| WO2001070720A2 (en) | 2000-03-21 | 2001-09-27 | The Procter & Gamble Company | Carbocyclic side chain containing, n-substituted metalloprotease inhibitors |
| WO2001090077A1 (en) | 2000-05-19 | 2001-11-29 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
| AU2002228316A1 (en) | 2001-01-29 | 2002-08-12 | Insight Strategy And Marketing Ltd | Carbazole derivatives and their uses as heparanase inhibitors |
| JPWO2002074298A1 (ja) | 2001-03-21 | 2004-07-08 | 小野薬品工業株式会社 | Ｉｌ−６産生阻害剤 |
| JP2004535390A (ja) | 2001-05-07 | 2004-11-25 | スミスクライン・ビーチャム・コーポレイション | スルホンアミド |
| NZ541950A (en) | 2001-08-09 | 2007-02-23 | Ono Pharmaceutical Co | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
| GB0126157D0 (en) | 2001-10-31 | 2002-01-02 | Univ Aberdeen | Therapeutic compounds |
| AU2003221160A1 (en) | 2002-03-27 | 2003-10-08 | Shionogi And Co., Ltd. | Decomposition inhibitor for extracellular matrix of cartilage |
| ATE469903T1 (de) | 2002-09-04 | 2010-06-15 | Schering Corp | Zur behandlung von krebserkrankungen geeignete pyrazolopyrimidine |
| DE10251170A1 (de) | 2002-10-31 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| WO2004073619A2 (en) | 2003-02-14 | 2004-09-02 | Smithkline Beecham Corporation | Ccr8 antagonists |
| DK1638544T3 (da) | 2003-05-07 | 2008-03-31 | Univ Aberdeen | Ketoner og reducerede ketoner som terapeutiske midler til behandling af knogletilstande |
| JPWO2004106290A1 (ja) | 2003-05-14 | 2006-07-20 | キッセイ薬品工業株式会社 | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 |
| PE20050948A1 (es) | 2003-09-09 | 2005-12-16 | Japan Tobacco Inc | Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv |
| GB0324792D0 (en) | 2003-10-23 | 2003-11-26 | Sterix Ltd | Compound |
| EP1696915A1 (en) | 2003-12-19 | 2006-09-06 | Pfizer, Inc. | Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity |
| WO2005080367A1 (en) | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Ep2 receptor agonists |
| GB0405193D0 (en) | 2004-03-08 | 2004-04-21 | Medical Res Council | Compounds |
| EP1756025A1 (en) | 2004-05-05 | 2007-02-28 | Novo Nordisk A/S | Sulfonamide derivatives |
| GB0412553D0 (en) | 2004-06-04 | 2004-07-07 | Univ Aberdeen | Therapeutic agents for the treatment of bone conditions |
| WO2005123089A2 (en) | 2004-06-10 | 2005-12-29 | Kalypsys, Inc. | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
| RS20070076A (sr) | 2004-10-29 | 2008-09-29 | Astrazeneca Ab., | Novi derivati sulfonamida kao modulatori glukokortikoidnog receptora za lečenje zapaljenskih bolesti |
| EP1659113A1 (en) | 2004-11-08 | 2006-05-24 | Evotec AG | Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) |
| KR20080016649A (ko) | 2005-06-16 | 2008-02-21 | 화이자 인코포레이티드 | Ｎ-(피리딘-2-일)-술폰아미드 유도체 |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| TW200720261A (en) | 2005-08-31 | 2007-06-01 | Sankyo Co | Phenylene derivatives |
| SI1945632T1 (sl) | 2005-11-08 | 2014-03-31 | Vertex Pharmaceuticals Incorporated | Heterocikliäśni modulatorji za prenaĺ alce z atp-vezavno kaseto |
| EP1984344B1 (en) | 2005-12-29 | 2012-09-26 | Lexicon Pharmaceuticals, Inc. | Multicyclic amino acid derivatives and methods of their use |
| US7560597B2 (en) | 2007-03-08 | 2009-07-14 | The University Court Of The University Of Aberdeen | 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents |
| GB0705400D0 (en) | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
| WO2010025235A1 (en) | 2008-08-29 | 2010-03-04 | Regents Of The University Of Michigan | Selective ligands for the dopamine 3 (d3) receptor and methods of using the same |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
| GB0817208D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | Therapeutic apsap compounds and their use |
| GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
| EP3262028B1 (en) | 2014-12-17 | 2021-10-27 | Pimco 2664 Limited | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(-4hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use |
-
2015
- 2015-12-16 EP EP15810646.8A patent/EP3262028B1/en active Active
- 2015-12-16 HU HUE15810646A patent/HUE057569T2/hu unknown
- 2015-12-16 SI SI201531774T patent/SI3262028T1/sl unknown
- 2015-12-16 US US15/534,228 patent/US10005733B2/en active Active
- 2015-12-16 CA CA2970578A patent/CA2970578C/en active Active
- 2015-12-16 WO PCT/EP2015/080022 patent/WO2016097001A1/en not_active Ceased
- 2015-12-16 MA MA041587A patent/MA41587A/fr unknown
- 2015-12-16 HR HRP20211877TT patent/HRP20211877T1/hr unknown
- 2015-12-16 JP JP2017532715A patent/JP6650942B2/ja active Active
- 2015-12-16 AU AU2015367528A patent/AU2015367528B2/en active Active
- 2015-12-16 LT LTEPPCT/EP2015/080022T patent/LT3262028T/lt unknown
- 2015-12-16 CN CN201580072308.XA patent/CN107108508B/zh active Active
- 2015-12-16 ES ES15810646T patent/ES2899852T3/es active Active
-
2018
- 2018-06-19 US US16/011,718 patent/US20180297955A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018509380A5 (cg-RX-API-DMAC7.html) | ||
| JP2016529218A5 (cg-RX-API-DMAC7.html) | ||
| HRP20211877T1 (hr) | Spojevi n-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamida i n-(4-hidroksi-4-metil-cikloheksil)-4- (2-piridil)-benzensulfonamida i njihova terapijska uporaba | |
| HRP20171611T1 (hr) | N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamidi i n-(4-hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamidi i njihova terapeutska primjena | |
| Rothenberg et al. | Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib—response | |
| MX384828B (es) | Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso. | |
| JP2017538677A5 (cg-RX-API-DMAC7.html) | ||
| JP2019532084A5 (cg-RX-API-DMAC7.html) | ||
| JP2016508505A5 (cg-RX-API-DMAC7.html) | ||
| JP2014508752A5 (cg-RX-API-DMAC7.html) | ||
| MX393599B (es) | Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco | |
| JP2017511311A5 (cg-RX-API-DMAC7.html) | ||
| JP2017537080A5 (cg-RX-API-DMAC7.html) | ||
| JP2015508103A5 (cg-RX-API-DMAC7.html) | ||
| JP2019529518A5 (cg-RX-API-DMAC7.html) | ||
| JP2017520613A5 (cg-RX-API-DMAC7.html) | ||
| JP2015512943A5 (cg-RX-API-DMAC7.html) | ||
| MY189345A (en) | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient | |
| JP2017530171A5 (cg-RX-API-DMAC7.html) | ||
| JP2017517520A5 (cg-RX-API-DMAC7.html) | ||
| JP2015502926A5 (cg-RX-API-DMAC7.html) | ||
| JP2020502268A5 (cg-RX-API-DMAC7.html) | ||
| JP2016504325A5 (cg-RX-API-DMAC7.html) | ||
| JP2020515582A5 (cg-RX-API-DMAC7.html) | ||
| JP2016534048A5 (cg-RX-API-DMAC7.html) |